Repligen Corporation $RGEN Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lowered its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 2.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,112 shares of the biotechnology company's stock after selling 1,748 shares during the period. California State Teachers Retirement System owned about 0.11% of Repligen worth $8,201,681 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. ABS Investment Management LLC bought a new stake in Repligen in the second quarter worth about $191,016,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Repligen in the 2nd quarter valued at $52,000. Trust Co. of Vermont bought a new stake in Repligen in the 2nd quarter valued at $71,000. Harbor Investment Advisory LLC increased its position in Repligen by 198.9% during the 2nd quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company's stock worth $71,000 after purchasing an additional 348 shares in the last quarter. Finally, Allworth Financial LP bought a new position in shares of Repligen in the 2nd quarter worth about $71,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Activity

In other Repligen news, CFO Jason Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.60% of the company's stock.

Repligen Stock Performance

NASDAQ RGEN traded up $6.53 on Tuesday, reaching $174.53. The stock had a trading volume of 442,586 shares, compared to its average volume of 1,011,925. The company has a market cap of $9.85 billion, a P/E ratio of 239.40, a price-to-earnings-growth ratio of 3.01 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm has a fifty day moving average of $158.75 and a two-hundred day moving average of $135.52. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts anticipate that Repligen Corporation will post 2.06 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RGEN. Citigroup raised Repligen to a "buy" rating in a report on Tuesday, July 7th. Wells Fargo & Company lifted their target price on Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th. Weiss Ratings upgraded Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 13th. UBS Group increased their target price on shares of Repligen from $195.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Finally, Zacks Research raised shares of Repligen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Repligen presently has an average rating of "Buy" and a consensus price target of $168.57.

Repligen Profile

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company's portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.